Gynecologic Oncology
Clinical discussions on gynecologic malignancies, surgical approaches, and multimodal treatment strategies.
Recent Discussions
How would you treat refractory diarrhea in a patient with low grade serous ovarian cancer treated with Trametinib?
Trametinib is known to cause significant diarrhea with 43% of patients affected with grade 1 or 2 diarrhea in phase II/III trials1. The recently released abstract for NRG-GOG 0281 reported on progression-free and overall survival, as well as toxicities related to use of Trametinib versus standard of...
How do you counsel patients with a diagnosis of EIN regarding sentinel lymph node dissection?
Though sentinel LN biopsy is feasible in this situation, I'm not sure that it is cost-effective. Emerson et al (Obstet Gynecol 2019) reported that an overall cohort of >250 patients with EIN would need to undergo sentinel LN biopsy to identify one patient with metastatic endometrial cancer. Likewise...
Any differences in the PARP inhibitors with respect to development of anemia?
Not in my experience. I have noticed that Olaparib seems to be associated with more fatigue/lethargy and low-grade nausea than niraparib, but there is no actual fall in hemoglobin.
Would you consider HIPEC in patients with advanced ovarian cancer undergoing primary cytoreductive surgery?
HIPEC is hyperthermic intraperitoneal chemotherapy and is often administered as a onetime dose after cytoreductive surgery. HIPEC has been clinically used in malignancies that can impact the peritoneal surfaces. For the following two reasons I do not administer HIPEC during surgery for patients unde...
When is it too late to start PARP manitenance after adjuvant chemotherapy in BRCA mutated ovarian cancer who had a delay in completing genetic testing?
Niraparib's prescribing information specifies that in the first-line maintenance setting, patients should start treatment no later than 12 weeks after their most recent platinum-containing regimen. In the setting of maintenance after recurrent ovarian cancer, treatment should start no later than 8 w...
How would you approach post op management of a patient s/p BSO for cystic pelvic mass with fallopian STIC lesion on final pathology?
This is a great question! There are no definitive management criteria for patients with isolated serous tubal intraepithelial carcinoma (STIC) lesions. The incidence at the time of risk-reducing salpingo-oophorectomy (RRSO) ranges from 0.6 to 7% in women with BRCA1/BRCA2 mutations. In patients under...
How would you manage a patient with profound dyspareunia after pelvic radiation for anal cancer?
Thanks for bringing up this important topic that remains understudied, with historically widely underestimated incidences of post-radiotherapy dyspareunia. There is currently no standardized method or schedule for assessing post-treatment sexual dysfunction including vaginal stenosis and fibrosis (a...
Would you consider adjuvant chemotherapy in a young patient with stage IC1 Sertoli-Leydig cell tumor, moderately differentiated, with heterologous (rhabdosarcomatous) component and retiform elements?
This young patient has several high-risk criteria for recurrence. Thus, I favor offering her adjuvant systemic platinum-based chemotherapy with 6 cycles of carboplatin + paclitaxel.Background:Sertoli-Leydig cell tumors (SLCTs) are sex-cord stromal tumors and account for less than 0.5% of primary ova...
What adjuvant therapy would you offer for an incidental endometrioid adenocarcinoma of the ovary noted on LSO, who has only a 3mm residual disease on peritoneal biopsy from completion staging?
As I read your question, I interpret this as saying that besides the ovary, the only site of disease after complete surgical staging was a biopsy obtained of the peritoneum? If this is the case, i.e., the patient has > stage I disease, I would proceed with adjuvant platinum-based chemotherapy.
How do you approach the pharmacologic management of cancer-related fatigue?
After the above considerations mentioned in the question, management considerations regarding cancer-related fatigue depend on the stage of disease (advanced/metastatic disease vs not) and whether the patient is on active cancer therapy. For both groups, non-pharmacologic interventions have the high...